tbuckley/cabot-search huggingface dataset:
SAT-254-Incidence of hepatocellular carcinoma and mortality after HCV elimination by all-oral DAA therapy: Results from a large-scale, multicenter cohort study
Authors: Eiichi Ogawa, Norihiro Furusyo, Nomura Hideyuki, Kazufumi Dohmen, Kazuhiro Takahashi, Makoto Nakamuta, Akira Kawano, Takeaki Satoh, Aritsune Ooho, Koichi Azuma, Toshimasa Koyanagi, Eiji Kajiwara, Yasunori Ichiki, Masami Kuniyoshi, Kimihiko Yanagita, Hiromasa Amagase, Chie Morita, Rie Sugimoto, Shinji Shimoda, Masaki Kato, Jun Hayashi
Journal: Journal of Hepatology (2019)
THU-112-Real-world health care resource utilization and quality of life with G/P treatment: A pooled analysis from post-marketing observational studies
Authors: Alessio Aghemo, Stefan Bourgeois, Michael Gschwantler, Yuri Sanchez, Lois Larsen, Mark Bondin, Lorenzo Magenta, Tarik Asselah
Journal: Journal of Hepatology (2019)
Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46
Authors: Yen-Nien Liu, Shaoxi Niu, Wei-Yu Chen, Qingfu Zhang, Yulei Tao, Wei-Hao Chen, Kuo-Ching Jiang, Xufeng Chen, Huaiyin Shi, Aijun Liu, Jinhang Li, Yanjing Li, Yi-Chao Lee, Xu Zhang, Jiaoti Huang
Journal: Clinical Cancer Research (2019)

Abstract Purpose: The molecular targets for castration-resistant prostate cancer (CRPC) are unknown because the disease inevitably recurs, and therapeutic approaches for patients with CRPC remain less well understood. We sought to investigate regulatory mechanisms that result in increased therapeutic resistance, which is associated with neuroendocrine differentiation of prostate cancer and linked to dysregulation of the androgen-responsive pathway. Experimental Design: The underlying intracellular mechanism that sustains the oncogenic network involved in neuroendocrine differentiation and therapeutic resistance of prostate cancer was evaluated to investigate and identify effectors. Multiple sets of samples with prostate adenocarcinomas and CRPC were assessed via IHC and other assays. Results: We demonstrated that leukemia inhibitory factor (LIF) was induced by androgen deprivation therapy (ADT) and was upregulated by ZBTB46 in prostate cancer to promote CRPC and neuroendocrine differentiation. LIF was found to be induced in patients with prostate cancer after ADT and was associated with enriched nuclear ZBTB46 staining in high-grade prostate tumors. In prostate cancer cells, high ZBTB46 output was responsible for the activation of LIF-STAT3 signaling and neuroendocrine-like features. The abundance of LIF was mediated by ADT-induced ZBTB46 through a physical interaction with the regulatory sequence of LIF. Analysis of serum from patients showed that cases of higher tumor grade and metastatic prostate cancer exhibited higher LIF titers. Conclusions: Our findings suggest that LIF is a potent serum biomarker for diagnosing advanced prostate cancer and that targeting the ZBTB46–LIF axis may therefore inhibit CRPC development and neuroendocrine differentiation after ADT.
PS-021-The development of portosystemic shunts depends on liver dysfunction rather than on PlGF-driven neoangiogenesis
Authors: Katharina Lampichler, Lukas Reider, Alek Stadlmann, Benedikt Simbrunner, Mattias Mandorfer, Theresa Bucsics, Rafael Paternostro, Ulrika Asenbaum, Thomas Reiberger
Journal: Journal of Hepatology (2019)
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial
Authors: Sibylle Loibl, Denise Treue, Jan Budczies, Karsten Weber, Albrecht Stenzinger, Wolfgang D. Schmitt, Wilko Weichert, Paul Jank, Jenny Furlanetto, Frederick Klauschen, Thomas Karn, Nicole Pfarr, Gunter von Minckwitz, Markus Möbs, Christian Jackisch, Christine Sers, Andreas Schneeweiss, Peter A. Fasching, Christian Schem, Michael Hummel, Marion van Mackelenbergh, Valentina Nekljudova, Michael Untch, Carsten Denkert
Journal: Clinical Cancer Research (2019)

Next-generation sequencing (NGS) can be used for comprehensive investigation of molecular events in breast cancer. We evaluated the relevance of genomic alterations for response to neoadjuvant chemotherapy (NACT) in the GeparSepto trial.Eight hundred fifty-one pretherapeutic formalin-fixed paraffin-embedded (FFPE) core biopsies from GeparSepto study were sequenced. The panel included 16 genes for mutational (AKT1, BRAF, CDH1, EGFR, ERBB2, ESR1, FBXW7, FGFR2, HRAS, KRAS, NRAS, SF3B1, TP53, HNF1A, PIK3CA, and PTEN) and 8 genes for copy-number alteration analysis (CCND1, ERBB2, FGFR1, PAK1, PIK3CA, TOP2A, TP53, and ZNF703).The most common genomic alterations were mutations of TP53 (38.4%) and PIK3CA (21.5%), and 8 different amplifications (TOP2A 34.9%; ERBB2 30.6%; ZNF703 30.1%; TP53 21.9%; PIK3CA 24.1%; CCND1 17.7%; PAK1 14.9%; FGFR 12.6%). All other alterations had a prevalence of less than 5%. The genetic heterogeneity in different breast cancer subtypes [lum/HER2neg vs. HER2pos vs. triple-negative breast cancer (TNBC)] was significantly linked to differences in NACT response. A significantly reduced pathologic complete response rate was observed in PIK3CA-mutated breast cancer [PIK3CAmut: 23.0% vs. wild-type (wt) 38.8%, P < 0.0001] in particular in the HER2pos subcohort [multivariate OR = 0.43 (95% CI, 0.24-0.79), P = 0.006]. An increased response to nab-paclitaxel was observed only in PIK3CAwt breast cancer, with univariate significance for the complete cohort (P = 0.009) and the TNBC (P = 0.013) and multivariate significance in the HER2pos subcohort (test for interaction P = 0.0074).High genetic heterogeneity was observed in different breast cancer subtypes. Our study shows that FFPE-based NGS can be used to identify markers of therapy resistance in clinical study cohorts. PIK3CA mutations could be a major mediator of therapy resistance in breast cancer.
PS-095-MerTK-mediated cytokine secretion mediates a cross-talk between M2c macrophages and hepatic stellate cells to induce fibrosis
Authors: Mirella Pastore, Alessandra Caligiuri, Chiara Raggi, Elisabetta Rovida, Giovanni Di Maira, Salvatore Petta, Fabio Marra
Journal: Journal of Hepatology (2019)
Association of falls with health related quality of life (HRQOL) in older cancer patients: A population based longitudinal study.
Authors: Allison Magnuson, Chintan Pandya, William Dale, Lisa Lowenstein, Chunkit Fung, Supriya Gupta Mohile
Journal: Journal of Clinical Oncology (2015)

e20524 Background: Falls are common in older adults and decrease HRQOL in the non-cancer population. To our knowledge, this is the first study to evaluate the association of falls with longitudinal change in HRQOL in older cancer patients. Methods: A linked dataset between the Medicare Health Outcomes Survey (MHOS) and Surveillance Epidemiology and End Results (SEER) registry from 2006-2011 was analyzed. Patients who reported no history of falls on their baseline survey and completed a follow-up survey were included. The independent variable was self-reported history of ≥ 1 falls reported on follow-up survey (“interval fall”). Analysis of covariance models were used to estimate the independent association of a fall history with changes in physical component survey (PCS) and mental component survey (MCS) HRQOL scores. Results: 6,313 older patients were included in the analysis. Interval episode of ≥ 1 falls occurred in 1,021 patients (average time between baseline and follow-up survey 1.86±0.54 yrs). Baseline HRQOL was lower in patients who experienced an interval fall compared to those without (PCS: 37.51±11.62 vs. 41.43±11.28, MCS: 51.63±10.63 vs. 54.02±9.41; p < 0.001). Interval episode of falling was significantly associated with decline in mean scores of PCS and MCS HRQOL, after controlling for baseline HRQOL scores and covariates (demographics, cancer-specific variables [type, stage, previous surgery/radiation], and geriatric issues; see table). Conclusions: Falls are independently associated with a significant prospective decline in physical and mental HRQOL in older cancer patients. Cancer survivorship care plans for older adults should incorporate fall prevention counseling. Parameter PCS SE Pr > |t| MCS SE Pr > |t| Interval fall No Ref Ref Yes -1.54 0.26 < 0.001 -1.71 0.27 < 0.001 Age ≥ 65-70 Ref > 70-75 -0.31 0.34 NS 0.23 0.36 NS > 75-80 -0.81 0.34 0.018 -0.02 0.36 NS > 80-85 -1.15 0.36 0.014 -0.61 0.37 NS > 85 -1.36 0.39 0.005 -0.88 0.41 0.03 ADL Independent Ref Ref ≥ 1 dependent -7.87 0.24 < 0.001 -2.75 0.23 < 0.001 Comorbidity 0 Ref Ref 1 -2.22 0.23 < 0.001 0.31 0.31 NS 2-3 -4.98 0.21 < 0.001 -0.10 0.30 NS > 3 -8.43 0.25 < 0.001 -0.33 0.37 NS Depression No Ref Ref Yes -1.23 0.32 < 0.001 -10.94 0.35 < 0.001
Abstract IA05: Genomic approaches to drug discovery
Authors: Todd Golub
Journal: Clinical Cancer Research (2018)

Abstract It is now becoming possible to bring powerful genomic methods to bear on the process of drug discovery. This talk will illustrate 1) the use of the Connectivity Map, a large-scale effort to develop a compendium of gene expression signatures of cellular state; 2) the use of PRISM, a new multiplexed, high-throughput approach to screening cancer cell lines for anticancer activity; and 3) the use of cancer models (cell lines and patient-derived xenografts) in discovery, with particular focus on clonal drift in these models and the impact of that drift on drug sensitivity. Citation Format: Todd Golub. Genomic approaches to drug discovery [abstract]. In: Proceedings of the AACR Conference on Advances in Sarcomas: From Basic Science to Clinical Translation; May 16-19, 2017; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(2_Suppl):Abstract nr IA05.
LBP-26-Magnetically controlled capsule endoscopy as a non-invasive tool for risk stratification of gastroesophageal varices in compensated cirrhosis (CHESS1801): A prospective multicenter study
Authors: Shuai Wang, Hua Mao, Weiling Hu, Shaoqin Jin, Li Yang, Chunqing Zhang, Chaohui He, Ruihua Shi, Xuan Zhu, Yanna Liu, Yasong Li, Juqiang Han, Guoan Li, Fan Li, Feichuang Jia, Dong Ji, Yifei Huang, Fangfang Lv, Xiao Liang, Haishan Xu, Qing Xu, CHANGQING YANG, Mingyan Zhang, Lifen Wang, Jing Wang, Ping Xie, Lulin Deng, Xuejia Lu, Chuan Liu, Xiujun Cai, Jinlin HOU, Xavier Dray, Xiaolong Qi
Journal: Journal of Hepatology (2019)
FRI-241-Barriers to HCV elimination among drug users: HepCare-Spain
Authors: Juan Macias Sanchez, María Iglesias, Beatriz Rioja, Bartolomé Baena, Evangelina Claro, Edmundo Cartagena, Juan C. Hornillos, M Mar Vázquez, José Osuna, M Carmen Gordillo, Coral Guerrero, Carmen Sánchez, Jesús Gómez-Mateos, Juan A. Pineda
Journal: Journal of Hepatology (2019)
Abstract P087: Use of Tobacco Products Among LGBTQ: Results From 2016 Surveys &amp; Focus Groups
Authors: Aida L Giachello, Thanh-Huyen Vu, Thomas J Payne, Rose M Robertson, Carlos Rodriguez, Allison Groom, Kandi Walker, Joy Hart, Sarah Langdon, Victoria Okhomina, Anshula Kesh, Samantha R Seale, Elena Navas-Nacher, Erika Murillo, Mario Sims, Patricia Salazar-Mitchell, Robyn Landry, Venoncia Bates-Ambrus
Journal: Circulation (2017)

Background: Cigarette smoking has been reported to be high among Lesbian, Gay, Bisexual, Transgendered and Queer (LGBTQ) populations. However, in-depth information on perception, knowledge, attitudes and behaviors, is limited. Methods: We analyzed 2016 data from the AHA-Tobacco Regulatory Addiction Center (A-TRAC) study on multi-ethnic LGBTQ groups living primarily in Chicago and New York City, ages 18-64, smokers and non-smokers. Twenty-nine focus groups and 99 individual surveys were conducted to obtain socio-demographic-economic characteristic and in-depth information on tobacco use, including cigarette smoking. Atlas.ti and SAS 9.4 were used for data analyses. Results: Of 99 participants, 58.8% of LGBTQ individuals reported smoking 100+ cigarettes during their life time; 49.5% (n=49) reported current cigarette smoking; and 17% reported frequent or occasional use of e-cigarette, e-hookah and/or other types of vaping. Age (25+) and low household income (&lt;$20,000) were significantly associated with the use of cigarette smoking. While 70.2% stated that cigarette smoking is very dangerous to health and 43.2% of respondents said that tobacco use is a very serious problem in the LGBTQ community, current smokers were unlikely to quit smoking (67%). Focus group discussions revealed that smoking a cigarette is a form of stress relief, a way of “expressing yourself”, and a way of “fitting in”. Heavy marketing by the tobacco industry as well as stress associated with social discrimination, family and friend rejections and limited income, were also factors identified with tobacco use. These findings were particularly true among transgender women and bisexual men and women. Conclusions: Cigarette smoking was high among the LGBTQ individuals in our sample and they seems unlikely to quit. Social stressors appear to be a strong contributing factor. Educational efforts and culturally appropriate messages to this population, are critical.
Targeted sequencing to confirm clinical diagnosis of Li-Fraumeni syndrome.
Authors: Vaijayanti Gupta, Ashraf U Mannan, Pooja Agrawal, Manimala Sen, Satish Sankaran, Vikram Vitthal, Vaibhavi Pathak, N.S.N Swetha, Divya Vishwanath, Gouri Deshpande, Kiran Kumari, Rupali Gadkari, Jaya Singh, Ravikiran Lakshmikeshava, Payal Manek, Manasa B.P., Disha Awasthy, Mohammed Yousuff, Suman Kapoor, Kalyanasundaram Subramanian
Journal: Journal of Clinical Oncology (2015)

e22052 Background: High throughput targeted sequencing is emerging as an invaluable tool for the oncologist, both for molecular characterization of the tumors and for hereditary risk assessment for cancer susceptibility. Li-Fraumeni syndrome (LFS) is a hereditary cancer syndrome, which predisposes an individual to developing several types of cancer such as sarcoma, premenopausal breast cancer, pancreas, colon carcinomas, tumors of the brain. It is usually associated with an early onset and typically inherited in an autosomal dominant manner. Germline mutations in the TP53 gene are associated with LFS gene in over 90% cases. We demonstrate the clinical utility of a low cost NGS (next-generation sequencing) based test for the detection of LFS associated TP53 mutations in patients/families meeting clinical criteria for LFS. Methods: 10 independent cases of clinically diagnosed LFS were subjected to targeted deep sequencing of the TP53 gene using our laboratory developed NGS test and Illumina’s Trusight Germline Cancer panel. Both panels were independently validated for technical performance and reach > 99% accuracy, sensitivity, specificity and reproducibility. SNP concordance was found to be 100% between both the panels. Sanger validation was performed for a few selected loci to establish accuracy. Sanger validation was also performed wherever additional family members were available. Results: We performed clinical validation of the laboratory developed NGS test for detection of mutations in the TP53 gene and confirm molecular diagnosis of LFS. In 8 of the 10 clinically diagnosed LFS patients, a pathogenic or a likely pathogenic variant was found and confirmed by Sanger sequencing, wherever DNA from additional family members were available. Conclusions: This data thus demonstrate the clinical utility of NGS based testing for germline cancer detection and the clinical validation of our laboratory developed risk assessment test for LFS.
SAT-190-Specific genetic elements in HBsAg C-terminus profoundly affect HBsAg levels in vivo, hamper HBsAg secretion in vitro and alter HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection
Authors: Lorenzo Piermatteo, Arianna Battisti, Luca Carioti, Olympia Anastasiou, Upkar S. Gill, Luna Colagrossi, Ada Bertoli, Marianna Aragri, Alessandra Iuvara, Vincenzo Malagnino, Carlotta Cerva, Miriam Lichtner, Claudio M. Mastroianni, Giuseppe Maria De Sanctis, Paoloni Maurizio, Massimo Marignani, Caterina Pasquazzi, Nerio Iapadre, Terenzio Mari, Giustino Parruti, Jacopo Vecchiet, Loredana Sarmati, Massimo Andreoni, Angelico Mario, Sandro Grelli, Patrick Kennedy, Jens Verheyen, Francesca Ceccherini Silberstein, Carlo Federico Perno, Valentina Svicher, Romina Salpini
Journal: Journal of Hepatology (2019)
FRI-363-Iron metabolism imbalance is associated with increased mortality following orthotopic liver transplantation
Authors: Fallet Elodie, Rayar Michel, Camus Christophe, Houssel-Debry Pauline, Jezequel Caroline, legros Ludivine, Uguen Thomas, Robert-Bouchet Martine, Boudjema Karim, Guyader Dominique, Edouard Bardou-Jacquet
Journal: Journal of Hepatology (2019)
Doubles trouble-85 cases of ocular trauma in badminton: clinical features and prevention
Authors: Jie Yu, Yan Chen, Jingpeng Miao, Meng Zhao, Caixia Keng, Xiaojie Wang, Jianjun Guo, Yi Liu
Journal: British Journal of Sports Medicine (2019)

To describe ocular injuries caused by badminton and to explore the implications for future prevention strategies.We enrolled 85 patients with ocular trauma caused by badminton. Information collected from patients included type of game, instigator, instrument of injury and lessons in badminton from a professional, and ocular trauma information such as type of injury, treatment and final outcomes.The 85 patients (52 men, 33 women) were aged 15-65 years with an average age of 42.9 (±10.7) years. In 60 cases the player was hit by a shuttlecock and in 25 the player was hit by a racquet. 73 cases occurred in doubles matches and 10 in singles matches. In 31 cases the trauma was caused by an opponent and in 52 cases by a partner; 2 cases involved bystanders, not players. About 70% (43/61) of the injured and 82% (40/49) of the instigators had not received badminton lessons from a professional. 80 injuries were non-penetrating and 5 were penetrating. There were 58 cases with hyphaema, 36 with secondary glaucoma, 23 with lens subluxation and 2 with retinal detachment. Surgery comprised phacoemulsification or lensectomy and vitrectomy in 16 cases, silicone oil tamponade in 2 cases, trabeculectomy in 3 cases and direct cyclopexy in 5 cases.The vast majority of the badminton related eye injuries occurred among doubles players and were instigated by the injured person's partner. Non-penetrating injury was more frequent; penetrating injury was usually more serious. We recommend that badminton players use protective eyewear and receive safety education and professional coaching/instruction on techniques to protect against serious eye injuries.
Abstract 17472: Interruption of Classic CD40L-CD40 Signaling But Not of the Novel CC40L-Mac-1 Interaction Limits Arterial Neointima Formation in Mice
Authors: Florian Willecke, Shilpa Tiwari, Benjamin Rupprecht, Dennis Wolf, Natalie Hoppe, Bianca Dufner, Peter Stachon, Ingo Hilgendorf, Karlheinz Peter, Peter Libby, Christoph Bode, Andreas Zirlik
Journal: Circulation (2012)

Background: The co-stimulatory immune molecule CD40L figures prominently in a variety of inflammatory conditions including arterial disease. Recently, we made the surprising finding that CD40L medi...
Using near-infrared enhanced thermozyme and <i>scFv</i> dual-conjugated Au nanorods for detection and targeted photothermal treatment of Alzheimer's disease
Authors: Dongni Liu, Wei Li, Xiaoyu Jiang, Shuju Bai, Jiyang Liu, Xutong Liu, Yuhua Shi, Ziyu Kuai, Wei Kong, Renjun Gao, Yaming Shan
Journal: Theranostics (2019)

Investigation of targeting inhibitors of Aβ aggregation, heme-Aβ peroxidase-like activity and efficient detectors of Aβ aggregation, are of therapeutic value and diagnostics significance for the treatment of Alzheimer's disease (AD).Due to the complex pathogenesis of AD, theranostics treatment with multiple functions are necessary.Herein we constructed the NIR absorption property of gold nanorods (GNRs) loaded with single chain variable fragment (scFv) 12B4 and thermophilic acylpeptide hydrolase (APH) ST0779 as a smart theranostic complex (GNRs-APH-scFv, GAS), which possesses both rapid detection of Aβ aggregates and NIR photothermal treatment that effectively disassembles Aβ aggregates and inhibits Aβ-mediated toxicity.Methods: We screened targeting anti-Aβ scFv 12B4 and thermophilic acylpeptide hydrolase as amyloid-degrading enzyme, synthesized GAS gold nanorods complex.The GAS was evalued by Aβ inhibition and disaggregation assays, Aβ detection assays, Aβ mediated toxicity assays in vitro.In vivo, delaying Aβ-induced paralysis in AD model of Caenorhabditis elegans was also tested by GAS.Results: In vitro, GAS has a synergistic effect to inhibit and disassociate Aβ aggregates, in addition to decrease heme-Aβ peroxidase-like activity.In cultured cells, treatment with GAS reduces Aβ-induced cytotoxicity, while also delaying Aβ-mediated paralysis in CL4176 C.elegans model of AD.Furthermore, the photothermal effect of the GAS upon NIR laser irradiation not only helps disassociate the Aβ aggregates but also boosts APH activity to clear Aβ.The GAS, as a targeting detector and inhibitor, allows real-time detection of Aβ aggregates.Conclusion: These results firstly highlight the combination of scFv, APH and nanoparticles to be theranostic AD drugs.Taken together, our strategy provides a new thought into the design of smart compounds for use as efficiently therapeutic and preventive agents against AD.Moreover, our design provides broad prospects of biomedical strategy for further theranostics application in those diseases caused by abnormal protein.
Sarcomas of the digestive tract (excluding GISTs) (SDT): A study of 63 patients from the French Sarcoma Group (GSF) database.
Authors: Clemence Toullec, Jean-Michel Coindre, Jean-Yves Blay, Dominique Ranchere, Pierre Meeus, Eberhard Stoeckle, Binh Bui, Sylvie Bonvalot, Axel Le Cesne, Philippe Terrier, Florence Duffaud, Francois Bertucci, Didier Cupissol, Nicolas Isambert, Sophie piperno Neumann, Karine Baumstarck, Sebastien Salas
Journal: Journal of Clinical Oncology (2015)

e21533 Sarcomas of the digestive tract (excluding GISTs) (SDT): a study of 63 patients from the French Sarcoma Group (GSF) database Background: The natural history of SDT has been rarely considered. We describe the histoclinical Â characteristics of SDT from the GSF database and analyze prognostic factors. Methods: We performed univariate with Fischer test and multivariate analysis with Cox regression for Overall Survival (OS), Metastasis-Free Survival (MFS), Local Recurrence-Free Survival (LRFS) and Disease free survival (DFS). Results: Twenty-one out of 84 patients (25%) who were metastatic at diagnosis were excluded. We restricted our analysis to patients with local disease to obtain a more homogeneous population (N=63). SDT represent about 0.8% of all soft tissue sarcomas. The median age was 60 years (range 18-83). Tumor locations were small intestine 34.9%, colon 23.8 %, stomach 19%, rectum 12.3%, oesophagus 4.8%, duodenum 4.8 %. Median tumor size was 8.5 cm (range 0,3-30). The most frequent tumor types were leiomyosarcoma (44.5%) and unclassified sarcoma (23.8%). 48.1% of cases were grade 3. 90.3% of patients underwent first surgery : 27.4% were treated in a GSF referral center. 75.5% patients had R0 resection. Surgery was followed by radiotherapy for 11.9% patients. Adjuvant or/and neoadjuvant chemotherapy was given only to 9 (15,0%) patients. The 5-year OS, MFS, LRFS and DFS rates were 60.1%, 74.1%, 78.2% and 54.5% respectively. Multivariate analysis retained unclassified sarcoma histological type for predicting OS (p = 0.036; OR = 3.33). Surgery in referral center appears as a factor of good prognosis in terms of DFS in univariate analysis (p = 0.048). Conclusions: Unclassified SDT had a significantly poorer OS compared with others histotypes of sarcoma. The 5-years MFS and LRFS rates appeared similar compared to sarcomas of other locations. This retrospective study underscores the importance of referral care center with a multidisciplinary sarcoma team. Â Â
FRI-489-Downstaging by 90-yttrium radioembolization of unresectable locally advanced hepatocellular carcinoma: A single center experience
Authors: Carolina Martelletti, Margherita Diotallevi, Amedeo Calvo, Nadia Russolillo, Alessandro Ferrero, Rodolfo Rocca, Marco Tabone
Journal: Journal of Hepatology (2019)